Resistance to Tyrosine Kinase Inhibitors
Resistance to Tyrosine Kinase Inhibitors
edited by Daniele Focosi.
- Cham, Switzerland Springer 2016
- 1 recurso en línea (XIII, 188 p.) 8 ilustraciones, 6 ilustraciones en color
- Resistance to Targeted Anti-Cancer Therapeutics 2196-5501 .
- Resistance to Targeted Anti-Cancer Therapeutics .
Tyrosine Kinase Signaling Pathways in Normal and Cancer Cells -- Resistance to Tyrosine Kinase Inhibitors in different types of solid cancer -- The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview -- Resistance to FLT3 Inhibitors -- Resistance to ALK inhibitors -- Resistance to Angiokinase Inhibitors -- Indications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors.
The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.
9783319460918
10.1007/978-3-319-46091-8 doi
Resistencia a los medicamentos
Cáncer--Investigación
RC271.P76 / R475 2016 EB
Tyrosine Kinase Signaling Pathways in Normal and Cancer Cells -- Resistance to Tyrosine Kinase Inhibitors in different types of solid cancer -- The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview -- Resistance to FLT3 Inhibitors -- Resistance to ALK inhibitors -- Resistance to Angiokinase Inhibitors -- Indications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors.
The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.
9783319460918
10.1007/978-3-319-46091-8 doi
Resistencia a los medicamentos
Cáncer--Investigación
RC271.P76 / R475 2016 EB